| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:DDX3-IN-2
CAS:1919828-81-1
Purity:95% Package:2mg;5mg;10mg
|
Urea, N-[4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl]-N'-(2-methylphenyl)- manufacturers
- DDX3-IN-2
-
- $149.00
-
2026-07-27
- CAS:1919828-81-1
- Purity:
- Supply Ability: 10g
|
| | Urea, N-[4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl]-N'-(2-methylphenyl)- Basic information |
| | Urea, N-[4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl]-N'-(2-methylphenyl)- Chemical Properties |
| density | 1.18±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 13.83±0.70(Predicted) | | color | Off-white to gray |
| | Urea, N-[4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl]-N'-(2-methylphenyl)- Usage And Synthesis |
| Uses | DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance[1]. | | Biological Activity | DDX3-IN-2 is an active DEADbox polypeptide 3 (DDX3) inhibitor with an IC50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance[1].
DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase[1].
DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg[1].DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values[1]. | | in vivo | DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg[1].
DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values[1]. | Animal Model: | Wistar rats[1] | | Dosage: | Tail vein injection | | Administration: | 20 mg/kg | | Result: | Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg.
|
| Animal Model: | Rats[1] | | Dosage: | I.v. bolus injection (Pharmacokinetic Analysis) | | Administration: | 10 mg/kg; 0~25 hours | | Result: | Rapidly eliminated the half-life elimination and the plasmatic clearance values.
|
| | IC 50 | HIV | | References | [1]. Brai A, et al. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proc Natl Acad Sci U S A. 2016;113(19):5388-5393. |
| | Urea, N-[4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl]-N'-(2-methylphenyl)- Preparation Products And Raw materials |
|